Free Newsletter
'Super-flu' outbreak highlights need for new drugs
Researchers are scrambling to get a better fix on a new variety of drug-resistant super flu. Healthcare workers in the U.S. and the Netherlands say the H1N1 'A' virus is loaded with a genetic variant that is resistant to Tamiflu, a first-line therapy used to protect the most vulnerable patients. And they are calling for new drugs and tests to combat the virus.
Research teams on two continents report the rapid spread of the virus with the gene mutation labelled H274Y. The Dutch team noted that four people were evidently infected by the virus in the hospital and two died from it.
"The study confirmed that circulating H274Y-mutated A (H1N1) viruses can retain significant pathogenicity and lethality, as shown in these elderly or immunocompromised patients, underlining the urgency for the introduction of new and effective antiviral agents and therapeutic strategies," the Dutch team reported.
The U.S. team, meanwhile, says that 98.5 percent of the H1N1 A viruses tested in the U.S. contained drug-resistant strains. "The emergency of oseltamivir resistance has highlighted the need for the development of new antiviral drugs and rapid diagnostic tests that determine viral subtype or resistance, as well as improved representativeness and timeliness of national influenza surveillance for antiviral resistance."
- read the report from the Belfast Telegraph
Comments
Perhaps flu researchers will be interested in testing an anti-viral drug sold under the name Arbidol in Russia, since it appears to operate quite differently than currently available drugs.
szpdnoje http://rmvhsflj.com vgahxdgh zvhupqsf
puozhjzl http://qupfhjox.com zyhgqnxv xbddwsog
Post new comment
Paid Research Reports
- The Specialty Pharma Market Outlook: Key players, new company growth models and emerging opportunities
- Investigating Clinical Trial Costs: Comparative analysis of trial cost components in key geographies
- Clinical Trial Recruitment Strategies: Optimizing patient recruitment and retention in late stage clinical trials
- Pipeline Insight: Therapeutic Cancer Vaccines - Prospect of first approval set to reinvigorate interest from major companies
- Stakeholder Opinions: Vaccines in Emerging Markets (Asia) - Opportunities in China, India, South Korea and Taiwan
- Big Pharma Performance Before, During and Beyond the Global Recession





SHARE
WITH: